NCT06964113 - A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Ulcerative Colitis

Interventions

DRUG

Filgotinib Maleate

Administered as oral tablets.

Trial Locations (14)

RECRUITING

Eisai Site #13, Busan

RECRUITING

Eisai Site #8, Busan

RECRUITING

Eisai Site #6, Daegu

RECRUITING

Eisai Site #2, Daejeon

RECRUITING

Eisai Site #7, Jungnam

RECRUITING

Eisai Site #10, Seoul

RECRUITING

Eisai Site #12, Seoul

RECRUITING

Eisai Site #14, Seoul

RECRUITING

Eisai Site #1, Seoul

RECRUITING

Eisai Site #3, Seoul

RECRUITING

Eisai Site #5, Seoul

RECRUITING

Eisai Site #9, Seoul

RECRUITING

Eisai Site #4, Suwon

RECRUITING

Eisai Site #11, Yangsan